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BACKGROUND. The survival of patients with head and neck squamous cell carci-
noma (HNSCC) remains unaffected despite recent therapeutic advances. To re-
verse this trend, reliable and clinically applicable markers of tumor aggressiveness
must be identified. One such marker may be the tumor-associated macrophage
content. The authors hypothesized that tumor-associated macrophages contribute
to HNSCC aggressiveness, and the objective of the current study was to prove this
hypothesis using mRNA expression analysis and a large cohort of clinical speci-
mens.
METHODS. Oligonucleotide microarray analysis was performed on a prospective
cohort of 20 patients with previously untreated oral cavity or oropharynx squa-
mous cell carcinoma (OC/OP SCCA) and on normal oropharyngeal mucosa from 4
patients. After determining whether macrophage chemoattractants were produced
by tumors, conditioned media from three HNSCC cell lines were used to quantify
macrophage migration in an in vitro assay. A high-density tissue microarray of 102
patients with previously untreated OC/OP SCCA was stained immunohistochemi-
cally for CD68 to identify tissue macrophages, and the results were correlated with
clinicopathologic data and survival.
RESULTS. Monocyte chemoattractant protein 1 was up-regulated significantly in
tumors compared with normal mucosa (P  0.0025; fold change  1.89). All
University of Michigan SCC tumor cell line conditioned media caused a significant
increase in macrophage migration (P  0.05). Tissue microarray data revealed that
macrophage content of the primary tumor was associated strongly with lymph
node metastasis (P  0.0001), extracapsular lymph node spread (P  0.0001), and
advanced clinical disease stage (P  0.0002). When it was evaluated along with
other clinicopathologic data, the macrophage content was found to be an inde-
pendent predictor of lymph node metastasis (P  0.0001).
CONCLUSIONS. Primary tumor macrophage content is a strong predictor of tumor
aggressiveness in HNSCC. Cancer 2004;101:2779 – 87.
© 2004 American Cancer Society.
KEYWORDS: high-density tissue microarray, migrated monocytes, monocyte che-
moattractant protein 1, tumor aggressiveness, squamous cell carcinoma, head and
neck cancer.
Head and neck squamous cell carcinoma (HNSCC) will affect55,000 Americans and will result in 13,000 deaths this year alone.
Advances in both surgical and nonsurgical therapeutics have led to
increased local tumor control in recent years. However, overall mor-
tality rates have not improved due to tumor recurrences at regional
and distant sites of metastasis. To impact the survival of these pa-
tients, molecular and histologic markers must be identified that will
help target tumors with a propensity for metastatic spread. Treat-
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ments tailored to these specific tumor determinants
may reduce metastasis and thus enhanced cure rates.
To date, no reliable or clinically applicable marker of
tumor aggressiveness has been identified for HNSCC.
One such putative marker of tumor aggressiveness
that has been identified in other malignancies is leu-
kocytic infiltration of the tumor, commonly known as
tumor-related leukocytosis (TRL).1 Over a 7-year pe-
riod Kasuga et al. investigated 227 patients with lung
carcinoma.1 Among these patients, 33 tumors, which
were predominately nonsmall cell lung carcinoma
(NSCLC), were identified with TRL on pathologic ex-
amination. These patients also had elevated levels of
serum granulocyte–macrophage-colony stimulating
factor, interleukin 6, and granulocyte-colony stimulat-
ing factor. It is interesting to note that patients with
TRL had a significantly reduced overall survival com-
pared with patients who had similarly staged tumors
without TRL.
The pathophysiology and mechanism by which
TRL and, more specifically, monocytosis effects tumor
behavior may be related to a substantial increase in
tumor angiogenesis. White al.2 showed in NSCLC that
tumor cocultured with peripheral blood monocytes
produced dramatically more proangiogenic cytokines
compared with tumor that was grown alone. Endothe-
lial cell migration also was enhanced by the condi-
tioned media from the cocultured cells compared with
tumor cells alone. Furthermore, it has been demon-
strated that macrophages are important independent
sources of proangiogenic cytokines on lung carci-
noma. Synthesizing the available data, we hypothe-
sized that tumor-associated macrophages (TAMs)
contribute to HNSCC aggressiveness. To evaluate this
hypothesis, we performed gene microarray expression
analysis on fresh tumor specimens. After confirming
the up-regulation of genes that are monocyte che-
moattractants, functional studies were performed us-
ing conditioned media from well established HNSCC
cell lines to investigate their effect on monocyte mi-
gration. Finally, the impact of TAMs on tumor aggres-
siveness and patient survival was evaluated using a
large tissue microarray with extensive clinical/patho-
logic data and follow-up.
METHODS AND MATERIALS
Tissue Samples and Cell Lines
A prospective cohort of 20 patients with newly diag-
nosed, previously untreated oral cavity (OC)/oropha-
ryngeal (OP) squamous cell carcinoma (SCC) who pre-
sented to the University of Michigan Medical Center
between February 2001 and December 2001 was in-
vestigated by mRNA expression analysis. All patients
underwent primary tumor resection and cervical
lymphadenectomy, and pathologic staging was per-
formed. There were 7 AJCC Stage I–II tumors (lymph
node negative tumors) and 13 Stage III–IV tumors
(lymph node positive). At the time of surgical resec-
tion, a sample of the primary tumor was snap frozen
in liquid nitrogen. Samples were embedded in optimal
cutting temperature freezing media (OCT; Miles Sci-
entific, Naperville, IL) and stored at  80 °C for RNA
extraction. A surgical pathologist evaluated a cryo-
tome section (5 m) from each block using hematox-
ylin and eosin staining. Areas of tissue containing at
least 70% tumor cellularity were selected for RNA iso-
lation. Normal controls for the array studies included
OC mucosa samples from 4 patients without cancer
who underwent surgical treatment for obstructive
sleep apnea and primary cell explants of OC keratin-
ocytes.
RNA Isolation
Total cellular RNA was extracted from the tumor sam-
ples and cell lines as described previously.3 Samples
were homogenized using Trizol reagent (Life Technol-
ogies, Gaithersburg, MD) and purified according to
the manufacturer’s instructions. RNA samples were
purified further on RNeasy spin columns (Qiagen, Va-
lencia, CA). RNA quality was assessed by 1% agarose
gel electrophoresis in the presence of ethidium bro-
mide.3
Microarray Analysis
Preparation of cRNA and hybridization to commer-
cially available HG_U95Av2 microarrays (Affymetrix,
Santa Clara, CA) was performed according to the man-
ufacturer’s protocols, as outlined previously.3–14 These
were general-purpose arrays that were not designed
for any particular subset of genes. Microarrays were
then scanned, and probe intensities were extracted
from the image (GeneArray scanner and Microarray
Suite 4.0; Affymetrix). Each probe set on the array
typically consisted of 16 individual, 25-base oligonu-
cleotide features complementary to specific cDNA,
called perfect match (PM) probes, and 16 identical
probes with a sequence that had been altered at the
central base, called mismatch (MM) probes. Publicly
available software was used to process the probe in-
tensities to obtain normalized results.14 Probe pairs
for which PM-MM   200 on the standard were
removed from the analysis, and the remaining PM-
MM differences were averaged for each probe set on
each microarray by discarding the 25% highest and
lowest differences and averaging the remaining differ-
ences. The intensities for each microarray were nor-
malized to the standard using a piece-wise linear
function that made 99 evenly spaced quintiles agree
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with the corresponding quantiles in the distribution of
the standard. Fold changes were computed as the
ratio of group means after first replacing means that
were  100  100. Normalized intensities were log
transformed by mapping x to log(max(x  100,0)
 100) prior to performing statistical tests. One-sided
signed-rank tests of PM-MM differences for each
probe set on each array were used to determine the
number of detectable transcripts.
Conditioned Media and Chemotaxis Assays
University of Michigan (UM) head and neck carci-
noma cell lines UM-SCC 9, 11b, and 38 were grown in
standardized conditions (1  106 cell per flask, 37 °C,
5% CO2, conditioned PBM media) until confluent. Me-
dia from the flask was flash frozen in 5 mL aliquots at
 20 °C. Media was thawed on ice immediately before
single use.
Chemotaxis assay
In vitro monocyte chemotaxis was performed in mod-
ified Boyden chambers (Neuroprobe, Cabin John,
MD), as described previously.4 Peripheral blood
mononuclear cells were isolated from heparinized
whole blood using Ficoll–Hypaque gradient centrifu-
gation. The bottom wells of blind well chemotaxis
chambers were filled with either 1) conditioned media
from each cell line treated with control immunoglob-
ulin G (IgG) antibody (1:500 dilution) or 2) condi-
tioned media treated with anti-CCR2 antibody. Filters
were placed over the wells, and the top wells were
filled with freshly isolated human peripheral blood
mononuclear cells (normal nonsmoking donor; 3
 106 cells/mL).4 Chambers were placed in humidi-
fied, 37 °C, 5% CO2 incubators for 1.5 hours. Filters
were then removed, stained, and mounted on slides.
Migrated cells were counted in five high-power fields
(HPF) per well. Each condition was run in triplicate,
and the experiments were repeated three times. Re-
sults were expressed as the mean  standard error of
the mean of cells per HPF.
Immunohistochemical staining of the tissue microarray
The validation of increased macrophage content in
metastatic tumors was investigated using immunohis-
tochemical analysis on a tissue microarray comprised
of 102 independent patient tumor samples. All pa-
tients for this validation group presented to the Uni-
versity of Michigan Hospital between 1997 and 2000
with newly diagnosed, previously untreated OC and
OP SCC (Table 1). None of the patients from the gene
array portion of the study were included in the tissue
microarray validation group. All patients underwent
pathologic staging after surgical tumor resection and
lymphadenectomy (69 lymph node-positive tumors
and 33 lymph node-negative tumors). The mean age
was 57 years in the lymph node-positive validation
group and 58 years in the lymph node-negative group.
The mean follow-up was 22 months in the lymph
node-positive group and 28 months in lymph node-
negative group. The mean disease-free interval was 20
months for the lymph node-positive group and 28
months for lymph node-negative group. Significant
tobacco and alcohol exposure was present in both
groups. A head and neck pathologist identified and
marked representative areas of tumor and normal
squamous mucosa from each patient’s paraffin-em-
bedded primary tumor block. A high-density tissue
microarray was constructed from each individual
block using 3 replicate tumor cores (0.6 mm in great-
est dimension) and 1 normal mucosa core per patient.
Cryotome sections (5 m) were then cut from the
TABLE 1
Descriptive Statistics on Demographic and Clinical Variables
Variable Value 95% CI
Total no. of patients 102 —
Age (yrs)
Mean  SD 56.3  14.6 —
Median 56.0 53.4–59.2
Range 33–74 —
Median follow-up (mos.) 41.1 36.0–45.3
No. of male patients (%) 76/102 (74.5) 66.1–83.0
No. with positive lymph nodes (%) 69/102 (67.7) 58.6–76.7
No. with each no. of positive lymph nodes (%)
0 33/102 (32.4) —
1 21/102 (20.6) —
2 13/102 (12.80) —
3 10/102 (9.8) —
 3 25/102 (24.5) —
No. with ECS (%) 40/102 (39.2) 29.7–48.7
No. with early T classification (T1–T2) (%) 37/100 (37.0) 27.5–46.5
No. each with T classification (%)
T0 2/102 (2.0) —
T1 8/102 (7.8) —
T2 29/102 (28.4) —
T3 27/102 (26.5) —
T4 36/102 (35.3) —
No. with perineural invasion (%) 19/98 (19.4) 11.6–27.2
No. with clinical Stage IV disease (%) 62/102 (60.8) 51.3–70.3
No. in each clinical stage (%)
Stage 1 6/102 (5.9) —
Stage 2 16/102 (15.7) —
Stage 3 18/102 (17.7) —
Stage 4 62/102 (60.8) —
No. with each type of primary differentiation (%)
Well 14/96 (14.6) —
Moderate 60/96 (62.5) —
Poor 22/96 (22.9) —
Three-yr overall survival rate (%) 64.6 54.9–74.4
SD: standard deviation; 95% CI: 95% confidence interval; ECS: extracapsular spread.
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high-density tissue microarray and stained for CD68.
The slides were placed in TBST, and immunohisto-
chemistry was performed using the Envision  Mouse
kit from Dako Cytomation (Dako Corporation, Carpin-
teria, CA). The CD68 primary antibody (Dako Cytoma-
tion) was incubated for 30 minutes at room tempera-
ture at a dilution of 1:1600. Appropriate positive and
negative isotype control antibodies were utilized. Uti-
lizing digital image capture, each core of the tissue
microarray was examined after staining for CD68. All
core samples were analyzed by a single examiner who
was blinded with regards to each patient’s clinical
information. Cells were considered positive if cyto-
plasmic staining was observed. Representative cores
were reviewed with a head and neck pathologist for
confirmation of analysis. Each core was then given an
absolute count for the number of cells that were pos-
itive for CD68 (representing macrophages).
Statistical Analysis
Because of multiple core measurements per patient,
the macrophage content is expressed as the weighted
mean  standard deviation, in which the weight is the
reciprocal of patient-wise, nonmissing macrophage
data points. The covariates of interest included the
metastasis of tumor to lymph nodes (positive vs. neg-
ative), the presence of lymph node tumor with extra-
capsular spread (ECS), T classification (T0, T1, T2, T3,
or T4), clinical stage (Stage I, II, III, or IV), perineural
invasion (presence vs. absence), primary differentia-
tion (poorly, moderately, or well differentiated), to-
bacco use (yes vs. no), alcohol use (yes vs. no), comor-
bidities (as measured by the Charleston comorbidity
index), age, gender, overall survival, and disease-free
survival.
To evaluate the association of macrophages with
covariates of interest, generalized linear models were
fit to the data using a generalized estimating equation
approach to account for both within-patient and be-
tween-patient variation derived from repeated macro-
phage measurements. A Poisson distribution was as-
sumed for macrophage counts. Over-dispersion was
corrected by a scale parameter that was estimated by
dividing the square root of the Pearson chi-square
statistic by degrees of freedom. Each covariate of in-
terest (except survival outcomes) was tested univari-
ately in the model as a main effect. The same analysis
was conducted on a subgroup of patients with early T
classification (T1 and T2).
Logistic regression was used to study the relation
between lymph node metastases (positive vs. nega-
tive) and macrophage content along with all the de-
mographic and clinical variables of interest, including
age, gender, comorbidities, alcohol use, tobacco use,
perineural invasion, primary differentiation, T classi-
fication, and clinical stage. Due to multicollinearity,
only T classification or clinical stage was included in
the model. The patient-wise median macrophage
count was used in the logistic regression model.
The predictive value of macrophage content on
survival outcomes was explored by the Kaplan–Meier
method and the log-rank test. The patient-wise me-
dian macrophage count was used in this analysis. In
addition, the log-rank test was used to compare the
homogeneity of survival rate between each category of
discrete clinical variables.
All statistical analyses were performed using SAS
software (version 8.2; SAS Institute Inc., Cary, NC). A
two-tailed P value  0.05 was considered statistically




Using the Affymetrix HG_U95Av2 GeneChip (which
consisted of 12625 probe sets representing approxi-
mately 9600 genes), we obtained gene expression pro-
files for 13 OC/OP SCC tumors that were metastatic to
cervical lymph nodes (lymph node positive), 7 non-
metastatic OC/OP SCC tumors (lymph node negative),
and 4 normal OC mucosa samples and normal OC
keratinocyte explants. Tumor samples averaged 7731
detectable probe sets, and normal samples averaged
7798 detectable probe sets (P  0.05). We identified
223 probe sets that represented angiogenesis-related
genes by reference to the literature and by searching
for the Gene Ontology term angiogenesis applied to
genes on LocusLink (available from URL: http://
www.ncbi.nlm.nih.gov/LocusLink/[accessed 8/30/2004]).
Two-sample Student t tests using log-transformed
data from tumor specimens versus normal mucosa
were performed specifically comparing expression
profiles of these 223 probe sets. Sixty-six probe sets
met statistical significance at a P value  0.05 and with
a fold change of 1.5. We randomly permuted the sam-
ple labels 1000 times using the same criteria on these
1000 data sets and obtained an average of only 7.1
qualifying probe sets. Fifty-two probe sets (40 genes)
were up-regulated in tumors compared with normal
mucosa controls (Fig. 1). Included in these were 3
probes sets that represented small inducible cytokine
A2, also know as monocyte chemotactic protein 1
(MCP-1).
Chemotaxis Assays
From our microarray data, the gene for MCP-1 was
expressed to a much greater degree in patients with
head and neck carcinoma than in normal tissue. To
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test the functional significance of this observation, we
evaluated whether head and neck carcinoma attracts
monocytes in vitro. We used UM-SCC cell lines 9, 11b,
and 38 and tested their attraction potential in stan-
dard monocyte chemotaxis assays. Standardized con-
trols determined a baseline chemotaxis of 3.2  0.61
cells per HPF. Tumor conditioned media-induced
chemotaxis was observed at an average of 17.3  3.05
cells per HPF. In the presence of the control antibody
(IgG) UM-SCC 9 induced 13.0  1.37 cells per HPF,
UM-SCC 11b produced a migration of 29.1  4.15 cells
per HPF, and UM-SCC 38 demonstrated a chemotaxis
of 39.9  8.7 cells per HPF. When the conditioned
media was treated with anti-CCR2 antibody (blocks
the MCP-1 receptor), UM-SCC 11b and 38 had a sig-
nificant decrease in monocyte chemotaxis compared
with the control antibody (Fig. 2).
Tissue Microarray and CD68 Staining
After illustrating increased genetic expression of
monocyte chemoattractant factors as well as in-
creased monocyte chemotaxis induced by condi-
tioned media from HNSCC cell lines, we stained the
high-density tissue microarray to investigate whether
these factors were correlated with primary tumor
macrophage content and with relevant clinical param-
eters (Fig. 3). The clinical parameters available for
analysis included 1) the presence of metastatic lymph
nodes, 2) the number of metastatic lymph nodes, 3)
the presence of extracapsular spread, 4) the T classi-
fication of the tumor, 5) the overall tumor stage, 6) the
presence of perineural spread, 7) the patient’s age, 8)
comorbidities, 9) tobacco use, 10) alcohol use, 11)
gender, and 12) tumor differentiation. Sixty-nine of
the 102 patients had positive lymph node status, and
33 patients had negative lymph node status. There
were 164 and 84 primary tumor cores available from
patients with positive and negative lymph node status,
respectively. Among 102 patients, 55 patients had nor-
mal core data available. Among the most significant
findings were the following: 1) There was a statistically
significant difference (P  0.0001) in the macrophage
contents between normal tissue and tumor tissue. The
average macrophage content was 11.1  14.6 and 38.0
 27.8 macrophages per HPF for normal cores and
tumor cores, respectively. 2) There was a marked dif-
ference (P  0.0001) in the macrophage content of
primary tumor tissue between patients with positive
FIGURE 1. This heat map illustrates
relative gene expression of the 66 probe
sets that were expressed differentially
between the patient’s primary tumors
and normal mucosa (represents 51
genes, including 40 up-regulated genes
and 11 down-regulated genes). Probe
sets yielded P values  0.05 (Student t
test), and fold-changes  1.5 are
shown for tumor versus normal mucosa.
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lymph nodes and patients with negative lymph nodes.
The average macrophage content of tumor cores from
patients with positive lymph nodes and patients with
negative lymph nodes were 46.7  27.9 macrophages
per HPF and 21.0  15.2 macrophages per HPF, re-
spectively. 3) Elevated macrophage counts in the pri-
mary tumor were correlated with lymph node metas-
tases (P  0.0001), lymph node ECS (P  0.0001),
advanced clinical stage (P  0.0002), and alcohol use
(P  0.003). 4) When the macrophage count was eval-
uated along with the other clinical parameters men-
tioned above, macrophage content was found to be an
independent predictor of lymph node metastasis (P
 0.0001). The subgroup analysis of patients with T1
and T2 tumors (n  36 patients) demonstrated a sim-
ilar pattern of statistical significance. Specifically, the
primary tumor core macrophage content was higher
in patients who had positive lymph nodes compared
with patients who had negative lymph nodes (P
 0.001), in patients who had ECS compared with
FIGURE 2. Chemotaxis assay: The x-axis represents the type of
University of Michigan head and neck squamous cell carcinoma cell line
assayed with control antibody (immunoglobulin G [IgG]) or with chemo-
kine-inhibiting antibody (anti-CCR2), which is a known inhibitor of mono-
cyte chemoattractant protein 1. The y-axis represents the number of
migrated monocytes per high-power field.
FIGURE 3. (A) This sample of tumor was stained with CD68 for macrophages from a patient with known positive lymph node status. (B) This sample of normal
mucosa tissue was stained with CD68 for macrophages. (C) This sample of tumor from a patient with negative lymph node status was stained with CD68 for
macrophages.
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patients who had no ECS (P  0.03), in patients who
had a later clinical disease stage compared with pa-
tients who had an earlier clinical disease stage (P
 0.03), and in patients who used alcohol compared
with patients who did not use alcohol (P  0.03).
Clearly, all these findings suggest that primary tumor
macrophage content correlates with aggressive tumor
behavior, even in small tumors, manifesting with in-
crease lymph node metastasis and an increased inci-
dence of ECS (Table 2).
Survival Analysis
Despite correlations with many poor prognostic fac-
tors, the macrophage count did not appear to corre-
late directly with disease-specific survival, overall sur-
vival, or time to disease recurrence. Disease-free
survival was affected negatively by lymph node me-
tastases (P  0.03), lymph node ECS (P  0.02), ad-
vanced clinical stage (P  0.04), advanced T classifi-
cation (P  0.02), and primary tumor perineural
invasion (P  0.02). Similarly, overall survival was
affected negatively by lymph node metastases (P
 0.04), lymph node ECS (P  0.04), primary tumor
perineural invasion (P  0.03), advanced T classifica-
tion (P  0.005), and advanced clinical stage (P
 0.01). Finally, variables that were found to be cor-
related with a shorter time to disease recurrence in-
cluded lymph node metastases (P  0.03), ECS (P
 0.02), primary tumor perineural invasion (P  0.02),
and clinical stage (P  0.04). Factors that were corre-
lated with overall survival, disease-specific survival,
and time to disease recurrence are summarized in
Table 3.
DISCUSSION
In the current study, we identified clinical and histo-
logic features that are predictive of decreased survival
in patients with OC/OP SCC. We also demonstrated a
strong correlation between primary tumor macro-
phage content and several of these predictive clinical
markers. Furthermore, our gene microarray analysis
and monocyte chemotaxis assays illustrate a propen-
sity for head and neck SCC to attract macrophages to
the primary tumor bed. Based on the presented data,
it is clear that macrophages increase head and neck
tumor aggressiveness. The mechanism for this effect is
elusive but is based on emerging evidence: It appears
that an increase in tumor angiogenesis may be a crit-
ical component.
It is well known that tumors that are unable to
create neovascularization are unable to grow beyond
the critical size of 2–3 mm.5 This angiogenesis and
resultant tumor growth is essential for subsequent
metastasis.5 A number of factors have been identified
as central to angiogenesis, including both proangio-
genic and antiangiogenic factors. Previous work has
shown that macrophages, in addition to the tumor
itself, serve as a source of proangiogenic cytokines.6
Thus, the infiltration of TAMs may be an important
step necessary for tumors to achieve critical size and
metastasis. Although it has been shown that macro-
phages in isolation are capable of proangiogenic ac-
tivity, Polverini7 demonstrated that macrophages
associated with tumor microenvironments are signif-
icantly more active in their cytokine production.
Therefore, the synergy between tumor and monocytes
creates a dramatic proangiogenic tumor phenotype.
Further solidifying this concept, Arenberg et al. exam-
ined the behavior of TAM in NSLC.4 Histologic analy-
sis of representative NSCLC revealed significant pres-
ence of infiltrating macrophages. After confirming
tumor-driven monocyte infiltration, Arenberg et al.
TABLE 2
Correlations with Elevated Macrophage Counts at the Primary
Tumor Site
Elevated macrophage count correlated with P value
Presence of metastatic lymph nodes  0.0001
Presence of extracapsular spread 0.0001
Advanced clinical stage 0.002
Alcohol use 0.003
Lymph node metastasis in small primary tumors (T1, T2) 0.001
Extracapsular spread in small primary tumors (T1, T2) 0.03
TABLE 3
The Effect of Various Clinical and Histologic Parameters on Survival







Lymph node metastasis 0.04a 0.03a  0.0001a
Age 0.24 0.67 0.56
Total comorbidities 0.31 0.77 0.87
Tobacco use 0.07 0.14 0.10
Alcohol use 0.38 0.48 0.42
Gender 0.37 0.33 0.25
Extracapsular spread 0.04a 0.02a 0.02a
Tumor differentiation 0.48 0.10 0.16
Tumor perineural invasion 0.03a 0.02a 0.02a
Tumor lymphatic invasion 0.12 0.04a 0.07
T classification 0.005a 0.02a 0.17
Clinical stage 0.01a 0.01a 0.04a
OS: overall survival; DFS: disease-free survival; TTR: time to recurrence.
a Statistically significant finding.
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also demonstrated that homogenates of their NSCLC
tumors induced significant monocyte chemotaxis and
production of proangiogenic CXC chemokines. Possi-
bly the most convincing work illustrating the impor-
tance of TAM in tumor progression and metastases
published to date comes from the work of Webb et al.,
Scholl et al., Sieuwerts et al., and Lin et al.8 –11 Using
transgenic mouse technology, these investigators were
able to create colony-stimulating factor 1 (CSF-1) null
mutant mice, which had a relative absence of mature
macrophages in many tissues, including the mam-
mary gland. In their studies, these researchers illus-
trated that the absence of macrophages did not affect
tumor formation and growth at the primary tumor site
(breast), but metastases of these tumors to the lungs
was significantly delayed. Furthermore, the restora-
tion of macrophage infiltration with expression of
CSF-1 restored macrophage infiltration at the primary
tumor site and dramatically accelerated tumor pro-
gression and metastases.11 Subsequent clinical studies
in breast carcinoma also have shown that marked
macrophage infiltration in these tumors is correlated
with a poor prognosis due to increased cytokine-me-
diated angiogenesis.12
Another potential mechanism by which TAM may
lead to increased tumor aggressiveness is by means of
altered antigen presentation. In recent years, it has
become increasingly evident that low numbers of ma-
ture dendritic cells in head and neck tumors are cor-
related with poor clinical outcomes.15 Furthermore, in
both renal cell carcinoma and melanoma, primary
tumors with a high macrophage content behaved
more aggressively and had lower numbers of activated
dendritic cells within the tumor itself.16,17 These re-
sults suggest that the tumor microenvironment is al-
tered by macrophages in such a way that it fails to
initiate the expected protective activation of dendritic
cells. Although to our knowledge this issue has not
been studied to date in SCC of the head and neck, this
is a very intriguing question and one that we will be
addressing in the near future.
In the current study, we demonstrated a correla-
tion between aggressive tumor behavior in head and
neck carcinoma and the level of primary tumor mac-
rophage infiltration. Specifically, patients who had tu-
mors with higher levels of macrophage infiltration
were more likely to develop lymph node metastases as
well as extracapsular spread of tumor through the
lymph nodes. In fact, macrophage content was found
to be an independent predictor of lymph node metas-
tasis in a multivariable analysis of tumor and patient
characteristics. Even more significant, however, was
the finding that there was a correlation between TAMs
and lymph node metastasis and ECS in T1 and T2
primary OC/OP tumors. However, it is interesting to
note that even though there was strong correlation
between the level of macrophage infiltration and the
presence of lymph node metastases and ECS (two
distinct and statistically significant negative prog-
nostic factors), TAM levels were not correlated with
overall survival, disease-specific survival, or time to
disease recurrence. This may have been due to the
relatively short follow-up in some of our patient
cohort and, as the data base matures, a stronger
correlation may emerge. A more likely explanation,
however, is the fact that there was wide variety in
the TAM count from patient to patient, and it is
unlikely that a reliable “cut-off point” can be deter-
mined above which tumors are more likely to me-
tastasize and below which they will not. Regardless,
the data from the current study and others clearly
indicate that macrophage infiltration plays a role in
the aggressive tumor phenotype, and further inves-
tigations are warranted to identify the mechanisms
of this effect. With further study, potential clinical
application of these findings may involve assessing
primary tumor macrophage content of early lesions
as a method of determining the need for selective
neck dissection or as a means of identifying patients
with particularly aggressive tumors as candidates
for neoadjuvant therapy.
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